Loading…
Ironwood Pharmaceuticals, Inc. is projected to rise to $4.69 by 2027, a +11% move from its current price of $4.23. IRWD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $4.06 | $4.23 | $4.41 | 0.00% |
| Aug 3 | $3.99 | $4.23 | $4.48 | +0.01% |
| Aug 4 | $3.94 | $4.23 | $4.54 | +0.01% |
| Aug 5 | $3.90 | $4.23 | $4.59 | +0.01% |
| Aug 6 | $3.86 | $4.23 | $4.63 | +0.01% |
| Aug 7 | $3.83 | $4.23 | $4.67 | +0.02% |
| Aug 8 | $3.80 | $4.23 | $4.71 | +0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.80 | $4.23 | $4.71 | +0.02% |
| Week 2 | $3.64 | $4.23 | $4.93 | +0.04% |
| Week 3 | $3.51 | $4.23 | $5.10 | +0.06% |
| Week 4 | $3.42 | $4.23 | $5.25 | +0.08% |
| Week 5 | $3.33 | $4.23 | $5.38 | +0.10% |
| Week 6 | $3.26 | $4.23 | $5.51 | +0.11% |
| Week 7 | $3.19 | $4.24 | $5.63 | +0.13% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals, Inc. (IRWD) is trading at $4.23 per share with a market capitalization of $696.31M, and it is ranked 2655.
The current price and market position are complemented by a long-term forecast that shows a path to higher levels over the coming years.
Forecasts map out a progression from 2026 through 2050, with 2026 avg $4.23, 2027 avg $4.69, 2028 avg $5.40, 2029 avg $7.31, 2030 avg $8.89, 2031 avg $8.98, 2032 avg $9.96, 2033 avg $10.40, 2034 avg $10.62, 2035 avg $13.82, 2040 avg $20.09, and 2050 avg $45.09.
ROI figures rise along the horizon, with 2027 ROI 10.9, 2028 27.6, 2029 72.9, 2030 110.2, 2031 112.2, 2032 135.6, 2033 145.9, 2034 151, 2035 226.8, 2040 375, and 2050 966.
A major floor 30.3% below — a decisive break under it would weaken the trend.
The nearest floor, 16.3% below — buyers have tended to step in here.
The nearest ceiling, 12.8% above — a clean break opens room to run.
A major ceiling 27.9% above — clearing it would confirm fresh momentum.
Key IRWD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRWD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.85 | Buy | $3.90 | Buy |
| MA 10 | $3.84 | Buy | $3.89 | Buy |
| MA 20 | $4.05 | Buy | $3.93 | Buy |
| MA 50 | $3.85 | Buy | $3.92 | Buy |
| MA 100 | $3.81 | Buy | $3.83 | Buy |
| MA 200 | $3.65 | Buy | $3.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.43 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 41.78 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 5.75 | Buy |
| Bollinger %B (20,2) | 0.63 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 58.10 | Neutral |
| Momentum (10) | 0.37 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 3.81 | Buy |
| ADX (14) | 15.33 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is mixed but leaning positive. The sentiment is BULLISH and the RSI14 sits at 60, suggesting capacity for upside without excessive overbought pressure. The price remains above the SMA50 of $3.85 and the SMA200 of $3.65, signaling a constructive trend.
Key near-term levels to watch are support at $3.54 and resistance at $4.77. The 30-day range trades between $3.24 and $5.53, highlighting a moderate trading band in the near term. The asset exhibits elevated volatility with an annualized volatility percentage of 80.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.04 | $4.23 | $4.98 | 0% | Neutral | |
| $3.57 | $4.69 | $6.59 | +11% | Neutral | |
| $3.94 | $5.40 | $8.00 | +28% | Bullish | |
| $5.14 | $7.31 | $11.28 | +73% | Bullish | |
| $6.04 | $8.89 | $14.18 | +110% | Bullish | |
| $5.92 | $8.98 | $14.73 | +112% | Bullish | |
| $6.39 | $9.96 | $16.78 | +136% | Bullish | |
| $6.49 | $10.40 | $17.92 | +146% | Bullish | |
| $6.45 | $10.62 | $18.68 | +151% | Bullish | |
| $8.19 | $13.82 | $24.81 | +227% | Bullish | |
| $10.58 | $20.09 | $39.08 | +375% | Bullish | |
| $20.29 | $45.09 | $98.37 | +966% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.04 | $4.23 | $5.01 | +0.00% |
| September 2026 | $3.45 | $4.15 | $5.16 | -1.99% |
| October 2026 | $3.50 | $4.24 | $5.36 | +2.28% |
| November 2026 | $3.31 | $4.05 | $5.18 | -4.49% |
| December 2026 | $3.12 | $3.85 | $4.98 | -4.97% |
Click any year to see its month-by-month IRWD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IRWD could reach as high as $4.98, with a base case around $4.23 and support toward $3.04 — roughly 0% from $4.23. A consolidation phase looks the most probable path here.
Expect IRWD to range from $3.57 to $6.59 through 2027. The $4.69 average target implies a +11% move from current prices. That is up +11% on the projected 2026 average. Price action looks broadly range-bound.
The IRWD price prediction for 2028 points to an average of $5.40 (low $3.94, high $8.00) — a potential gain of +28% on today's $4.23. Buyers look set to stay in control over this stretch.
In 2029, IRWD is projected to trade between $5.14 and $11.28, averaging $7.31 — a potential gain of +73% from today's $4.23. That is up +35% on the projected 2028 average. Momentum favours further upside here.
Ironwood Pharmaceuticals, Inc.'s 2030 outlook centres on $8.89, within a $6.04 to $14.18 range. That is up +22% on the projected 2029 average. That marks a +110% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, IRWD could reach as high as $14.73, with a base case around $8.98 and support toward $5.92 — roughly +112% from $4.23. Momentum favours further upside here.
Expect IRWD to range from $6.39 to $16.78 through 2032. The $9.96 average target implies a +136% move from current prices. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The IRWD price prediction for 2033 points to an average of $10.40 (low $6.49, high $17.92) — a potential gain of +146% on today's $4.23. Momentum favours further upside here.
In 2034, IRWD is projected to trade between $6.45 and $18.68, averaging $10.62 — a potential gain of +151% from today's $4.23. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Ironwood Pharmaceuticals, Inc.'s 2035 outlook centres on $13.82, within a $8.19 to $24.81 range. That is up +30% on the projected 2034 average. That marks a +227% change versus current levels. Momentum favours further upside here.
By 2040, IRWD could reach as high as $39.08, with a base case around $20.09 and support toward $10.58 — roughly +375% from $4.23. Buyers look set to stay in control over this stretch.
Expect IRWD to range from $20.29 to $98.37 through 2050. The $45.09 average target implies a +966% move from current prices. That is up +124% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IRWD today (≈ 236.406619 IRWD) could be worth
$10,659.64
+$9,659.64 (+966%) by 2050 · US Dollar
Based on the average projected IRWD price of $45.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRWDwould be worth at today's price.
$1,000 invested in IRWD on Jul 31, 2025 (≈ 1,315.78949 IRWD) would be worth
$5,565.79
+$4,565.79 (+456.6%) today · 5.57× · US Dollar
Based on a IRWD entry price of $0.76 vs. today's $4.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.71 | $1,140.16 | +14.0% |
| 1 month ago | $4.12 | $1,026.7 | +2.7% |
| 3 months ago | $4.44 | $952.7 | -4.7% |
| 6 months ago | $4.94 | $856.28 | -14.4% |
| 1 year ago | $0.76 | $5,565.79 | +456.6% |
| All time (5.0y) ago | $13.27 | $318.76 | -68.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRWD forecast.
Our base-case forecast reaches $8.50 around 2030.
Implied market cap at $8.50: $1.4B
The multi-year forecast lays out a clear path to higher prices, with notable milestones in the 2030, 2040 and 2050 horizons. By 2030 the average forecast price is $8.89, with a potential range from $6.04 to $14.18 and an ROI of 110.2, underscoring a bullish tilt.
Beyond 2030, the trajectory remains bullish with 2031 through 2035 showing continued gains, including 2035 with an average of $13.82 and an ROI of 226.8. In the long run, the forecast points to substantial upside, with 2040 averaging $20.09 and 2050 averaging $45.09, corresponding to ROIs of 375 and 966 respectively. These figures imply growing investor interest and a strong long-term upshift, while noting that these are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast shows 2030 avg $8.89, min $6.04, max $14.18, roiPct 110.2, sentiment BULLISH.
The forecast indicates a bullish longer-term trajectory with 2029 avg $7.31, 2030 avg $8.89, and 2040 avg $20.09; roiPct 72.9, 110.2, and 375, with sentiment BULLISH. These are estimates, not guarantees.
Yes—the forecast for 2040 lists an avg of $20.09 and a max of $39.08, with roiPct 375 and sentiment BULLISH.
2026 min $3.04, avg $4.23, max $4.98, roiPct 0, sentiment NEUTRAL.
2050 min $20.29, avg $45.09, max $98.37, roiPct 966, sentiment BULLISH.
Ironwood Pharmaceuticals, Inc. Community Discussion
0Share your Ironwood Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.